Intra-arterial chemotherapy for malignant gliomas: A critical analysis

Interventional Neuroradiology

Volumn 17, Issue 3, 2011, Pages 286-295

  Burkhardt, J K ^a   Riina, H A ^a   Shin, B J ^a   Moliterno, J A ^b   Hofstetter, C P ^a   Boockvar, John A ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Glioblastoma multiforme; Perivascular niche; Selective intra arterial niche disruption; Superselective intra arterial cerebral infusion

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CISPLATIN; ETOPOSIDE; IRINOTECAN; LOBRADIMIL; MANNITOL; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; NIMUSTINE; SUNITINIB; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; BLINDNESS; BLOOD BRAIN BARRIER; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN EDEMA; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER STEM CELL; DRUG DOSE ESCALATION; DRUG TARGETING; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; LEUKOENCEPHALOPATHY; LIVER CELL CARCINOMA; NEUROTOXICITY; NONHUMAN; RETINOBLASTOMA; RETINOPATHY; REVIEW; SEIZURE; STROKE; TUMOR RECURRENCE; TUMOR XENOGRAFT; VISUAL IMPAIRMENT;

EID: 80555139037     PISSN: 15910199     EISSN: None     Source Type: Journal    
DOI: 10.1177/159101991101700302     Document Type: Review

References (80)

1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003. (Pubitemid 40349502)
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996. (Pubitemid 40349501)
3. Andratschke N, Grosu AL, Molls M, et al. Perspectives in the treatment of malignant gliomas in adults. Anticancer Res. 2001; 21: 3541-3550. (Pubitemid 34224263)
4. Lefranc F, Rynkowski M, DeWitte O, et al. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009; 34: 3-35.
5. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466.
6. Nieder C, Adam M, Molls M, et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol. 2006; 60: 181-193. (Pubitemid 44709618)
7. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9: 157-173. (Pubitemid 43357943)
8. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics. 2009; 6: 539-546.
9. Desjardins A, Rich JN, Quinn JA, et al. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 2005; 10: 2645-2668. (Pubitemid 40905267)
10. Qureshi AI, Suri MF, Khan J, et al. Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. J Neurooncol. 2001; 51: 151-158. (Pubitemid 32435495)
11. Riina HA, Fraser JF, Fralin S, et al. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol. 2009; 8: 145-150.
12. Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood brain barrier disruption for recurrent malignant glioma. J Neurosurg. 2011; 114: 624-632.
13. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010; 17: 1234-1246.
14. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010; 21: 203-212.
15. Abramson DH, Dunkel IJ, Brodie SE, et al. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010; 117: 1623-1629.
16. Owens G, Javid R, Belmusto L, et al. Intra-arterial vincristine therapy of primary gliomas. Cancer. 1965; 18: 756-760.
17. Newton HB. Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol. 2005; 6: 519-530. (Pubitemid 43033781)
18. French JD, West PM, Von Amerongen FK, et al. Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. J Neurosurg. 1952; 9: 378-389.
19. Klopp CT, Alford TC, Bateman J, et al. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg. 1950; 132: 811-832.
20. Eckman WW, Patlak CS, Fenstermacher JD. A critical evaluation of the principles governing the advantages of intra-arterial infusions. J Pharmacokinet Biopharm. 1974; 2: 257-285.
21. Rapoport SI, Hori M, Klatzo I. Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol. 1972; 223: 323-331.
22. Neuwelt EA, Maravilla KR, Frenkel EP, et al. Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest. 1979; 64: 684-688. (Pubitemid 9237606)
23. Seldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol. 1953; 39: 368-376.
24. Riina HA, Knopman J, Greenfield JP, et al. Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interventional Neuroradiology. 2010; 16: 71-76.
25. Gobin YP, Cloughesy TF, Chow KL, et al. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology. 2001; 218: 724-732. (Pubitemid 32172554)
26. Saris SC, Blasberg RG, Carson RE, et al. Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg. 1991; 74: 763-772.
27. Cloughesy TF, Gobin YP, Black KL, et al. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol. 1997; 35: 121-131. (Pubitemid 27361680)
28. Iwadate Y, Namba H, Saegusa T, et al. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors. J Neurooncol. 1993; 15: 185-193. (Pubitemid 23136034)
29. Bullard DE, Bigner DD. Blood-brain barrier disruption in immature Fischer 344 rats. J Neurosurg. 1984; 60: 743-750. (Pubitemid 14165107)
30. Chiueh CC, Sun CL, Kopin IJ, et al. Entry of [3H]norepinephrine, [125I]albumin and Evans blue from blood into brain following unilateral osmotic opening of the blood-brain barrier. Brain Res. 1978; 145: 291-301. (Pubitemid 8322435)
31. Rapoport SI, Fredericks WR, Ohno K, et al. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol. 1980; 238: R421-431.
32. Neuwelt EA, Barnett PA, Frenkel EP. Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. Neurosurgery. 1984; 14: 154-160. (Pubitemid 14198777)
33. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol. 2004; 6: 300-305. (Pubitemid 39429833)
34. Neuwelt EA, Howieson J, Frenkel EP, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery. 1986; 19: 573-582. (Pubitemid 16006308)
35. Miyagami M, Tsubokawa T, Tazoe M, et al. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Med Chir (Tokyo). 1990; 30: 582-590.
36. Hori T, Muraoka K, Saito Y, et al. Influence of modes of ACNU administration on tissue and blood drug concentration in malignant brain tumors. J Neurosurg. 1987; 66: 372-378. (Pubitemid 17031464)
37. Hall WA, Doolittle ND, Daman M, et al. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol. 2006; 77: 279-284. (Pubitemid 44404394)
38. Guillaume DJ, Doolittle ND, Gahramanov S, et al. Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery. 2010; 66: 48-58; discussion 58.
39. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000; 88: 637-647. (Pubitemid 30056941)
40. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009; 27: 3503-3509.
41. Remsen LG, Pagel MA, McCormick CI, et al. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. Anesth Analg. 1999; 88: 559-567. (Pubitemid 29109022)
42. Neuwelt EA, Specht HD, Howieson J, et al. Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning. Am J Roentgenol. 1983; 141: 829-835. (Pubitemid 13006715)
43. Greene HS. The transplantation of tumors to the brains of heterologous species. Cancer Res. 1951; 11: 529-534.
44. Greene HS. The transplantation of human brain tumors to the brains of laboratory animals. Cancer Res. 1953; 13: 422-426.
45. Pantelouris EM. Absence of thymus in a mouse mutant. Nature. 1968; 217: 370-371.
46. Ovejera AA, Houchens DP. Human tumor xenografts in athymic nude mice as a preclinical screen for anti-cancer agents. Semin Oncol. 1981; 8: 386-393. (Pubitemid 12180590)
47. Bullard DE, Schold SC, Jr., Bigner SH, et al. Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol. 1981; 40: 410-427. (Pubitemid 12251824)
48. Neuwelt EA, Frenkel EP, D'Agostino AN, et al. Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res. 1985; 45: 2827-2833. (Pubitemid 15232757)
49. Neuwelt EA, Pagel M, Barnett P, et al. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Res. 1981; 41: 4466-4470. (Pubitemid 12201359)
50. Levin VA, Kabra PM, Freeman-Dove MA. Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg. 1978; 48: 587-593. (Pubitemid 8311446)
51. Hassenbusch SJ, Anderson JH, Colvin OM. Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions. J Neurooncol. 1996; 30: 7-18. (Pubitemid 26265765)
52. Schuster JM, Friedman HS, Archer GE, et al. Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Res. 1993; 53: 2338-2343. (Pubitemid 23156822)
53. Kurpad SN, Friedman HS, Archer GE, et al. Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. Cancer Res. 1995; 55: 3803-3809.
54. Remsen LG, McCormick CI, Sexton G, et al. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence. Clin Cancer Res. 1995; 1: 731-739.
55. Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol. 2009; 11: 301-310.
56. Zink WE, Foley CP, Dyke JP, et al. Novel microcatheters for selective intra-arterial injection of fluid in the rat brain. Am J Neuroradiol. 2009; 30: 1190-1196.
57. Dropcho EJ, Rosenfeld SS, Morawetz RB, et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium. J Clin Oncol. 1992; 10: 452-458.
58. Roosen N, Kiwit JC, Lins E, et al. Adjuvant intra-arterial chemotherapy with nimustine in the management of World Health Organization Grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Dusseldorf University. Cancer. 1989; 64: 1984-1994. (Pubitemid 19280392)
59. Vega F, Davila L, Chatellier G, et al. Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy. J Neurooncol. 1992; 13: 131-135.
60. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg. 1992; 76: 772-781.
61. Recht L, Fram RJ, Strauss G, et al. Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial. Am J Clin Oncol. 1990; 13: 125-131. (Pubitemid 20170264)
62. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
63. Feun LG, Wallace S, Yung WK, et al. Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Deliv. 1984; 1: 239-245. (Pubitemid 15187877)
64. Safdari H, Mompeon B, Dubois JB, et al. Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: a preliminary report. Surg Neurol. 1985; 24: 490-497. (Pubitemid 16256101)
65. Feun LG, Lee YY, Yung WK, et al. Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. Cancer Drug Deliv. 1986; 3: 147-156. (Pubitemid 16081257)
66. Kleinschmidt-DeMasters BK, Geier JM. Pathology of high-dose intraarterial BCNU. Surg Neurol. 1989; 31: 435-443. (Pubitemid 19130751)
67. Tonn JC, Roosen K, Schachenmayr W Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas - a complication of both ACNU and BCNU? J Neurooncol. 1991; 11: 241-242.
68. Follezou JY, Fauchon F, Chiras J. Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study. Neoplasma. 1989; 36: 349-352. (Pubitemid 19171603)
69. Clocchlatti L, Cartei G, Lavaroni A, et al. Intra-arterial chemotherapy with carboplatin (CBDCA) and vepesid (VP16) in primary malignant brain tumours. Preliminary findings. Interventional Neuroradiology. 1996; 2: 277-281. (Pubitemid 126489308)
70. Newton HB, Slivka MA, Stevens CL, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas. J Neurooncol. 2002; 56: 79-86. (Pubitemid 34256621)
71. Fortin D, Desjardins A, Benko A, et al. Enhanced chemotherapy delivery by intraarterial infusion and bloodbrain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer. 2005; 103: 2606-2615. (Pubitemid 40800541)
72. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729. (Pubitemid 350086473)
73. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-1972.
74. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009; 22: 633-638.
75. Sarin H, Kanevsky AS, Wu H, et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med. 2009; 7: 51.
76. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007; 11: 69-82. (Pubitemid 46054518)
77. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468: 829-833.
78. Hofstetter C, Boockvar J. Generation of neural stem cells: a team approach. Neurosurgery. 2010; 67: N22-23.
79. Hofstetter C, Boockvar J. Tapping an abundant resource: engineering pluripotent stem cells from blood. Neurosurgery. 2010; 67: N25
80. Fatoo A, Nanaszko MJ, Allen BB, et al. Understanding the role of tumor stem cells in glioblastoma multiforme: a review article. J Neurooncol. 2010; [Epub ahead of print].